Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lonza Group | London | Healthcare | Biotechnology & Medical Research | £37.05B | 67.6x | -1.55 | GBX 51,204.73 | -3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
arGEN X BV | London | Healthcare | Biotechnology & Medical Research | £32.13B | -971.5x | -11.78 | GBX 53,514.65 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab | London | Healthcare | Biotechnology & Medical Research | £9.94B | 19.2x | 1.4 | GBX 15,652.68 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | London | Healthcare | Biotechnology & Medical Research | £7.59B | 102.6x | -1.51 | GBX 3,587.87 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zealand Pharma | London | Healthcare | Biotechnology & Medical Research | £5.77B | -44.1x | 3.18 | GBX 8,248.74 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech L | London | Healthcare | Biotechnology & Medical Research | £1.91B | 17.3x | 0.12 | GBX 3,510.75 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Geron Corp | London | Healthcare | Biotechnology & Medical Research | £1.41B | -9.1x | -1.7 | GBX 232.47 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genus | London | Healthcare | Biotechnology & Medical Research | £1.22B | 154x | -1.9 | GBX 1,864 | 5.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.8% Upside | Upgrade to Pro+ | |
Intellia Therapeutics | London | Healthcare | Biotechnology & Medical Research | £828.01M | -1.9x | 1.24 | GBX 813.23 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Oxford BioMedica | London | Healthcare | Biotechnology & Medical Research | £448.12M | -3x | 0.03 | GBX 423 | -4.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17% Upside | Upgrade to Pro+ | |
PureTech Health PLC | London | Healthcare | Biotechnology & Medical Research | £348.12M | -6x | 0.06 | GBX 145.40 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Allergy Therapeutics | London | Healthcare | Biotechnology & Medical Research | £309.82M | -5.8x | -0.1 | GBX 6.50 | -4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Verastem | London | Healthcare | Biotechnology & Medical Research | £222.61M | -2x | -0.14 | GBX 491.17 | 7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Faron Pharmaceuticals Oy | London | Healthcare | Biotechnology & Medical Research | £183.09M | -4.6x | -1.24 | GBX 175 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Avacta Group | London | Healthcare | Biotechnology & Medical Research | £173.80M | -5.6x | -0.16 | GBX 47.50 | -4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bioventix | London | Healthcare | Biotechnology & Medical Research | £167.03M | 20.2x | -6.02 | GBX 3,200 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
4BASEBIO UK SOCIETAS | London | Healthcare | Biotechnology & Medical Research | £153.66M | -15.9x | 0.29 | GBX 1,200 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 50% Upside | Upgrade to Pro+ | |
Hvivo | London | Healthcare | Biotechnology & Medical Research | £129.27M | 7.3x | 0.02 | GBX 19 | -6.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Scancell | London | Healthcare | Biotechnology & Medical Research | £99.23M | -13.6x | -3.23 | GBX 9.66 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Corbus Pharmaceuticals Holdings | London | Healthcare | Biotechnology & Medical Research | £94.19M | -2.2x | -0.05 | GBX 768.18 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Futura | London | Healthcare | Biotechnology & Medical Research | £94.15M | -26x | -0.84 | GBX 31 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Editas Medicine | London | Healthcare | Biotechnology & Medical Research | £88.92M | -0.5x | -0.12 | GBX 111.81 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Batm Advanced Comm | London | Healthcare | Biotechnology & Medical Research | £83.60M | -236.8x | 1.55 | GBX 19.15 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Transgene | London | Healthcare | Biotechnology & Medical Research | £76.36M | -3x | -0.12 | GBX 57.44 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Adverum Biotechnologies | London | Healthcare | Biotechnology & Medical Research | £72.91M | -0.8x | -0.02 | GBX 354.73 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Inovio Pharmaceuticals | London | Healthcare | Biotechnology & Medical Research | £58.91M | -0.4x | -0.02 | GBX 162.48 | -8.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Nordic Nanovector | London | Healthcare | Biotechnology & Medical Research | £58.19M | -46.6x | GBX 18.65 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Biotec Pharmacon | London | Healthcare | Biotechnology & Medical Research | £51.50M | 163x | -2.02 | GBX 101.69 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
SkinBioTherapeutics | London | Healthcare | Biotechnology & Medical Research | £41.12M | -11.9x | -1.37 | GBX 18 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Relief Therapeutics Holding | London | Healthcare | Biotechnology & Medical Research | £40.56M | -1x | -0.02 | GBX 329.37 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |